Biogen (BIIB) said Monday it initiated dosing in its global phase 3 trial to evaluate the investigational drug, felzartamab, in adults with primary membranous nephropathy, a severe autoimmune kidney disorder with no approved treatments.
The company said the study will compare felzartamab to tacrolimus and enroll around 180 patients, with results expected in 2029.
The drugmaker said the study will assess remission rates at 104 weeks and track changes in proteinuria, anti-PLA2R antibody levels, and patient-reported outcomes.
The trial is one of three phase 3 studies Biogen launched this year for felzartamab, alongside programs in IgA nephropathy and late antibody-mediated kidney transplant rejection, it added.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。